887471-69-4

Usage

Uses

Used in Biochemical Research:
2-Fluoro-6-methylphenylboronic acid is used as a reagent in biochemical methods of study. It is particularly valuable for the synthesis of fluorinated boronic acid-appended pyridinium salts, which are compounds of interest in various chemical and biological applications.
Additionally, 2-Fluoro-6-methylphenylboronic acid is utilized in 19F NMR Spectroscopy for diol sensing. This application takes advantage of the compound's ability to form complexes with diols, which can be detected and analyzed using nuclear magnetic resonance spectroscopy. This technique is crucial for understanding the interactions between the compound and various biomolecules, which can be instrumental in the development of new sensors and analytical methods in the field of chemistry and biochemistry.

Upstream product

• 121-43-7 Trimethyl borate 
• 59907-13-0 2-bromo-1-fluoro-3-methylbenzene 

Downstream Products

• 1612288-72-8 2-(2-fluoro-6-methylphenyl)-5-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)-1H-pyrrolo[3,2-b]pyridine 
• 1586045-63-7 2-(2-fluoro-6-methylphenyl)thiazole-4-carboxylic acid 
• 1586041-52-2 N-(5-((2S,5R,6S)-5-amino-6-fluorooxepan-2-yl)-1-methyl-1H-pyrazol-4-yl)-2-(2-fluoro-6-methylphenyl)thiazole-4-carboxamide 
• 1586041-11-3 5-amino-N-(5-((2S,5R,6R)-5-amino-6-fluorooxepan-2-yl)-1-methyl-1H-pyrazol-4-yl)-2-(2-fluoro-6-methylphenyl)thiazole-4-carboxamide 

Relevant academic research and scientific papers

Pyridopyrimidinone compound and application thereof

The invention provides a pyridopyrimidinone compound with a structure as shown in a general formula (II) and application thereof. Researches prove that the compound provided by the invention can effectively inhibit KRAS G12C mutation. KRAS mutation accounts for a large proportion in tumors, no approved drug is obtained for treatment at present, and the compound provided by the invention has the potential to become a therapeutic drug for malignant tumors (especially non-small cell lung cancer (NSCLC) and colorectal cancer) carrying KRAS G12C mutation, and has a great application value.

New bicyclic compounds as crac channel modulators

The present invention relates to novel compounds which are inhibitors of CRAC channel activity. This invention also relates to pharmaceutical compositions containing them, process for their preparation and their use in therapy.

AZABENZOXAZOLES FOR THE TREATMENT OF CNS DISORDERS

The present invention relates to a7 nicotinic receptor agonists of formula (la) or (lb) as described herein and to a method for treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal an a7 nicotinic receptor agonist of formula (la) or (lb). It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant a7nicotinic receptor agonist of formula (la) or (lb).